Acetyl Hexapeptide-3 (Argireline)
SNARE complex inhibitor that reduces expression wrinkles through topical neuromuscular modulation — the 'Botox in a bottle' peptide.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
5 % – 10 %
Compound profile
Scientific & efficacy data
Cosmetic
Peptide profile
Limited human trials
Acetyl Hexapeptide-3 (Argireline)
5-10% concentration (cream or serum) · Once daily
Molecular formula
C35H62N14O11S
- Mol. weight
- 887.0 Da
- CAS number
- 616204-22-9
- PubChem
- 71587772
- Developed · 1999
- Antonio Ferrer Montiel and research team
University of California San Diego / University of Elche, Spain
Amino acid sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (Ac-EEMQRR-NH2), modeled on the N-terminal domain of SNAP-25Expression Wrinkle Reduction
Clinically demonstrated 48.9% reduction in periorbial wrinkles after 4 weeks through SNARE complex inhibition and neuromuscular modulation.
Non-Invasive Treatment
Provides botulinum toxin-like wrinkle reduction mechanism in a topical format — no needles, no neurotoxin, no downtime.
Safety Profile
Exceptional safety demonstrated in cytotoxicity studies with 100-fold margin over toxic references and no serious adverse effects in clinical trials.
Dosing
How much do I take?
5 % – 10 % · twice daily (morning and evening)
5 % – 10 %
Twice daily (morning and evening)
Covers timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for individuals seeking non-invasive reduction of expression lines and dynamic wrinkles & those with needle phobia who want botulinum toxin-like effects without injections
Best for
Individuals seeking non-invasive reduction of expression lines and dynamic wrinkles
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on individuals seeking non-invasive reduction of expression lines and dynamic wrinkles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those with needle phobia who want botulinum toxin-like effects without injections
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on those with needle phobia who want botulinum toxin-like effects without injections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
People targeting crow's feet, forehead lines, and glabellar creases
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on people targeting crow's feet, forehead lines, and glabellar creases. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals looking for preventive anti-wrinkle treatment to slow expression line formation
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on individuals looking for preventive anti-wrinkle treatment to slow expression line formation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Acetyl Hexapeptide-3 (Argireline) with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Topical
Route
Acetyl Hexapeptide-3 (Argireline) is administered Topical—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Acetyl Hexapeptide-3 demonstrates an excellent safety profile for topical cosmetic use with no serious adverse events reported in clinical studies.
At the 10% concentrations used in cosmetic formulations, systemic absorption is minimal and no neurotoxicity has been observed despite its mechanism of action on the neuromuscular junction. The peptide shows a safety margin of approximately 100-fold compared to toxic reference compounds.
Primary concerns are limited to local skin irritation in sensitive individuals, such as mild erythema, transient stinging, or contact dermatitis in those with peptide hypersensitivity.
Evidence comes from multiple clinical studies demonstrating safety at cosmetic concentrations, including 4-week dermatological safety trials showing no systemic toxicity or significant adverse effects. The mechanism of action is well-characterized in vitro and validated through efficacy studies.
Data suggests the peptide's large molecular size and poor transepidermal penetration provide a natural safety barrier, preventing systemic effects even with prolonged topical use.
Common side effects · experienced by some users
Mild Skin Irritation
Rare mild irritation in sensitive individuals, typically during initial use. Generally self-resolving.
Management: Start with once daily application. If persistent, reduce concentration or discontinue.
Transient Redness
Temporary redness at application site, particularly on thin or sensitive periorbital skin.
Management: Patch test before full application. Allow skin to acclimate over first few days.
Slight Dryness
Minor dryness when peptide solution is used without adequate moisturization in dry environments.
Management: Always follow with a hydrating moisturizer or use Argireline in a cream-based formulation.
Stinging on Compromised Skin
Brief stinging if applied to areas where skin barrier is disrupted (after exfoliation or sun exposure).
Management: Avoid application on freshly exfoliated or sunburned skin. Wait for barrier recovery before use.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Acetyl Hexapeptide-3 (Argireline)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Acetyl Hexapeptide-3 (Argireline) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Hyaluronic Acid — May be used together under medical guidance.
- Safe:Matrixyl (Palmitoyl Pentapeptide-4) — May be used together under medical guidance.
- Safe:Niacinamide — May be used together under medical guidance.
With medications
- Caution:Vitamin C at Very Low pH (<3.5) — Use with caution—discuss with your healthcare provider.
- Caution:Benzoyl Peroxide — Use with caution—discuss with your healthcare provider.
- Caution:Strong AHA/BHA Peels — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Acetyl Hexapeptide-3 (Argireline). Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Limited human trials · first signs weeks 1-2
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Acetyl hexapeptide-3 (Argireline) is a cosmetic peptide that mimics part of the SNAP-25 protein, which botulinum toxin targets.
It binds to muscle cell receptors and interferes with acetylcholine release at the neuromuscular junction, reducing muscle contraction that causes expression wrinkles. It works topically without injections, making it a non-invasive Botox alternative.
The deeper mechanism
Acetyl hexapeptide-3 is a synthetic hexapeptide acetylated at the N-terminus that mimics the sequence of SNAP-25 (synaptosome-associated protein of 25 kDa), a target of botulinum neurotoxin cleavage.
The peptide acts as a competitive substrate for SNARE complex formation on presynaptic nerve terminals, inhibiting the fusion of acetylcholine-containing synaptic vesicles with the presynaptic membrane.
This prevents acetylcholine release into the neuromuscular junction without permanently cleaving SNARE proteins (unlike botulinum toxin). Topical penetration is achieved through formulation with permeation enhancers, allowing dermal delivery to motor nerves innervating facial muscles.
Acetyl hexapeptide-3 produces reversible, dose-dependent reduction in muscle contraction and wrinkle depth, with effects building over 4-6 weeks of consistent application.
What to expect
Weeks 1-2
What you might notice
- SNARE complex modulation begins at the cellular level
- Neuromuscular signaling partially reduced in treated areas
- Surface wrinkle changes not yet visible
What's normal
- Full integration of Acetyl Hexapeptide-3 (Argireline) into physiological systems is established
- Long-term Acetyl Hexapeptide-3 (Argireline) response remains personalized to your physiology
- Acetyl Hexapeptide-3 (Argireline) tolerance is well-maintained with consistent dosing
What's next
- Maintain your established Acetyl Hexapeptide-3 (Argireline) protocol for sustained benefits
- Continue periodic monitoring to confirm Acetyl Hexapeptide-3 (Argireline) efficacy
- Review comprehensive Acetyl Hexapeptide-3 (Argireline) response with your provider
Weeks 2-4
What you might notice
- Expression lines begin to soften as reduced muscle contraction allows collagen relaxation
- Clinical data shows measurable roughness and wrinkle depth improvements emerging at 4 weeks
What's normal
- Acetyl Hexapeptide-3 (Argireline) is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Acetyl Hexapeptide-3 (Argireline)'s mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Acetyl Hexapeptide-3 (Argireline) dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Weeks 4-8+
What you might notice
- Maximum wrinkle reduction achieved (up to 48.9% improvement)
- Expression lines appear visibly diminished
- Continued application maintains results;
- effects are reversible within 4-8 weeks of discontinuation
What's normal
- Characteristic effects of Acetyl Hexapeptide-3 (Argireline) are becoming established
- Repeated Acetyl Hexapeptide-3 (Argireline) doses show predictable pharmacological effects
- Acetyl Hexapeptide-3 (Argireline) tolerance patterns are developing normally
What's next
- Evaluate Acetyl Hexapeptide-3 (Argireline) efficacy relative to treatment goals
- Discuss potential protocol adjustments with your healthcare provider
- Continue regular Acetyl Hexapeptide-3 (Argireline) monitoring at current frequency
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Acetyl Hexapeptide-3 (Argireline) over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
Is Argireline really 'Botox in a bottle'?
Argireline targets the same biological mechanism as botulinum toxin — SNARE complex inhibition at the neuromuscular junction — but through competitive binding rather than enzymatic cleavage. It is less potent than injected botulinum toxin (achieving ~50% wrinkle reduction vs. near-complete paralysis), but works non-invasively through topical application without needles, neurotoxin risks, or downtime.
How does Argireline compare to botulinum toxin injections?
Botulinum toxin provides stronger, more immediate wrinkle reduction (visible in 3-7 days, lasting 3-4 months) but requires injection, carries neurotoxin risks, and costs significantly more. Argireline provides gradual improvement over 4 weeks with approximately 50% wrinkle reduction, but is non-invasive, inexpensive, and has an excellent safety profile. Many practitioners recommend Argireline between injection appointments to extend results.
Can Argireline penetrate the skin effectively given its size?
At 887 Da, Argireline is relatively large for topical absorption. It primarily acts in the stratum corneum and superficial epidermis, with limited deeper penetration (0.22-0.54% skin penetration). Advanced formulation vehicles (O/W emulsions, W/O/W emulsions) improve delivery. Despite limited deep penetration, clinical efficacy is clearly demonstrated, likely through surface-level neuromuscular modulation.
Are the wrinkle-reducing effects permanent?
No. Argireline's effects are maintained only with continued application. Upon discontinuation, SNARE complex function normalizes and expression lines gradually return to their pre-treatment state within approximately 4-8 weeks. Consistent twice-daily application is needed to maintain wrinkle reduction.
What areas of the face respond best to Argireline?
Argireline works best on dynamic expression wrinkles — lines caused by repeated muscle movement. The most responsive areas include crow's feet (lateral periorbital lines), horizontal forehead lines, and glabellar frown lines. It is less effective on static wrinkles caused by photoaging or loss of skin elasticity unrelated to muscle contraction.
Further reading
History & related research
History · since 1999
The wrinkle fighter that puts the brakes on facial muscles
Acetyl Hexapeptide-3 is a six-part peptide made from amino acids. Scientists designed it to mimic how Botox works, but in a topical cream instead of injections.
Read the full history of Acetyl Hexapeptide-3 (Argireline)Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Acetyl Hexapeptide-3 (Argireline), on one page.